Epigral FY26 Profit Falls 7% Amid Rising Costs; Q4 Revenue Jumps 16%

Epigral Ltd reported its financial results for the fiscal year ended March 31, 2026. Annual profit after tax decreased by 7.19% to ₹331.97 Crore. However, the company saw a significant 16.57% rise in total income for the fourth quarter, reaching ₹735.59 Crore.

Latest Financial Results

For the full fiscal year 2026, total income saw a slight decrease of 0.90% to ₹2,542.16 Crore. Profit after tax for the year declined by 7.19% to ₹331.97 Crore.

In the fourth quarter (Q4 FY26), total income increased by 16.57% year-on-year to ₹735.59 Crore. Profit after tax for the quarter decreased by 6.84% to ₹80.95 Crore.

Epigral reported a reduction in its non-current borrowings, which fell to ₹333.69 Crore from ₹448.97 Crore in the prior fiscal year. The board has recommended a final dividend of ₹5.00 per equity share. The statutory auditors provided an unmodified opinion on the financial statements.

Why This Matters

These mixed results reflect a challenging business environment where rising expenses have impacted annual profitability, despite revenue growth in the latest quarter.

The company's efforts to reduce debt provide some financial stability, while the proposed dividend indicates a commitment to shareholder returns.

Company Background

Epigral Limited, previously known as Meghmani Finechem Ltd, is a leading integrated chemical manufacturer in India, founded in 2007.

The company has been shifting its business model from basic chlor-alkali products to higher-value derivatives and specialty chemicals. This aims to replace imports and improve its product range.

This strategy includes major investments in expanding capacities for key products such as Epichlorohydrin (ECH), CPVC resin, and Chlorotoluene.

Debt management has been a priority, with the company actively reducing its borrowings through equity raises and cash generated from operations.

What This Means for Shareholders

Shareholders are set to receive a proposed final dividend of ₹5.00 per equity share.

Lower debt levels are expected to strengthen the company's financial position and improve its balance sheet.

Effectively managing rising operating expenses will be crucial for converting revenue growth into higher net profits.

Potential Risks

Epigral faces risks from continued increases in operating expenses, which have pressured annual profitability despite revenue growth.

Concerns include profit margin pressure, evident in the Q4 profit after tax decline despite increased sales, and potential price volatility for commodity chemicals.

The company's operations are concentrated at a single manufacturing site in Dahej, Gujarat. This poses an operational risk should any unforeseen issues occur.

A further risk relates to the challenge against anti-dumping duty segregation for special-grade PVC, for which Epigral is the sole Indian producer.

Competitor Performance

Aarti Industries, a specialty chemicals peer, reported a revenue decline in Q1 FY26 due to broader economic factors, such as raw material price corrections.

Alkyl Amines Chemicals reported a profit decline in Q3 FY26, citing margin compression, pricing pressure, and weaker demand in some segments.

Key Financial Metrics

Non-current borrowings decreased from ₹448.97 Crore in FY25 to ₹333.69 Crore in FY26.

What Investors Will Watch

Investors will closely monitor management's commentary on strategies to control rising expenses and improve profit margins.

The outlook for key industries Epigral serves, including infrastructure, pharmaceuticals, and agrochemicals, will also be important.

The successful launch and ramp-up of new capacities for ECH and CPVC will be a key growth driver to monitor.

Shareholders will also be interested in the final payout details and timing of the proposed ₹5.00 dividend.